CHRS

COHERUS ONCOLOGY, INC.

CHRS · CIK 1512762 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20172024
Net Income$29M
20172024
Operating CF−$20M
20172024
Free Cash Flow
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue—————$0.1B$0.0B$0.0B
Cost of Revenue$0.1B$0.2B$0.1B$0.1B$0.0B———
Gross Profit—————$0.1B——
R&D Expense$0.1B$0.1B$0.2B$0.4B$0.1B$0.1B$0.1B$0.2B
SG&A Expense$0.2B$0.2B$0.2B$0.2B$0.1B$0.1B$0.1B—
Operating Income$-0.1B$-0.2B$-0.3B$-0.3B$0.2B$0.1B$-0.2B$-0.2B
Net Income$0.0B$-0.2B$-0.3B$-0.3B$0.1B$0.1B$-0.1B$-0.0B
EPS (Basic)$0.25$-2.53$-3.76$-3.81$1.85$0.56—$-1.71
EPS (Diluted)$0.25$-2.53$-3.76$-3.81$1.62$0.53—$-1.71

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.4B$0.6B$0.5B$0.7B$0.8B$0.4B$0.1B$0.2B
Current Assets$0.3B$0.5B$0.4B$0.6B$0.8B$0.3B$0.1B$0.1B
Cash & Equivalents$0.1B$0.1B$0.1B$0.4B$0.5B$0.2B$0.1B$0.1B
Total Liabilities$0.6B$0.8B$0.6B$0.6B$0.6B$0.3B$0.1B$0.1B
Current Liabilities$0.3B$0.3B$0.1B$0.2B$0.1B$0.1B$0.0B$0.0B
Stockholders' Equity$-0.1B$-0.2B$-0.1B$0.1B$0.3B—$-0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.2B$-0.2B$-0.0B$0.2B$0.0B$-0.2B—
Investing Cash Flow$0.2B$0.1B$-0.2B$-0.1B$-0.0B$-0.0B$-0.0B—
Capital Expenditures—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.2B$0.1B$0.1B$0.1B$0.2B$0.1B$0.1B—
← Companies